Skip to main content

Table 2 Base case model results after price negotiation

From: Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

Strategy Fruquintinib Placebo
Cost, USD 20,750.9 12,042.2
Effect, QALY 0.6404 0.4776
IC, USD 8708.7 –
IE, QALY 0.16275 –
ICER, USD per QALY 53,508.7 –
  1. Abbreviations: IC incremental cost, IE incremental effectiveness, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us